Half-year report · Q2
7733.TEDINET S100UNV8
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardIFRS
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥474.0bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥925.8bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥431.6bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥70.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.8bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥68.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥43.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥49.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥242.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥216.3bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥49.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥216.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.37T | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.53T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.62T | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥663.6bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥777.0bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥703.1bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥757.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥827.5bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥641.2bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥703.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥757.2bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥827.5bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥245.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥340.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥488.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥93.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥42.4bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥11.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥30.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥360.0bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥412.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥156.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥276.0bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥125.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥42.24 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥199.91 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥173.81 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥42.16 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥199.44 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥173.81 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 51.4% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.4% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 51.2% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥387m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥18.5bn |
| jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥26.8bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥89.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥9m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥18.6bn |
| jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥50.9bn |
| jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥28.5bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥22.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 683
| Item | Context | Value | Unit |
|---|---|---|---|
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -50035000000 | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -20057000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -20981000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | Prior1YTDDuration | -183000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | CurrentYTDDuration | － | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -63976000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -56465000000 | JPY |
| Decrease increase in deposit for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -26024000000 | JPY |
| Decrease increase in deposit for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -18536000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | Prior1YTDDuration | -2921000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | CurrentYTDDuration | － | JPY |
| Other fin cf IFRS | Prior1YTDDuration | -2095000000 | JPY |
| Other fin cf IFRS | CurrentYTDDuration | -957000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -125422000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -156741000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 7146000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | -2012000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | 282648000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | -95064000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | Prior2YearInstant | 205512000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | Prior1YearInstant | 340933000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | Prior1QuarterInstant | 488160000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | CurrentQuarterInstant | 245869000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 270867000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 159698000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 430565000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1028000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Sales to external customers IFRS | Prior1YTDDuration | 431593000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 14000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 3000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_ReportableSegmentsMember | 17000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_ReconcilingItemsMember | -17000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration | － | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 270881000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 159701000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_ReportableSegmentsMember | 430582000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1028000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_ReconcilingItemsMember | -17000000 | JPY |
| Net sales IFRS | Prior1YTDDuration | 431593000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 50909000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | -28542000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 22367000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 9000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -18609000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 3767000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 1172000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 6990000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |